No abstract available
MeSH terms
-
Aged, 80 and over
-
Alzheimer Disease / complications
-
Alzheimer Disease / diagnosis
-
Alzheimer Disease / drug therapy
-
Alzheimer Disease / psychology
-
Antidepressive Agents, Second-Generation / adverse effects
-
Antidepressive Agents, Second-Generation / therapeutic use*
-
Antipsychotic Agents / adverse effects
-
Antipsychotic Agents / therapeutic use*
-
Aripiprazole
-
Combined Modality Therapy
-
Comorbidity
-
Cyclohexanols / adverse effects
-
Cyclohexanols / therapeutic use*
-
Delirium / diagnosis
-
Delirium / drug therapy
-
Delirium / psychology
-
Depressive Disorder, Major / diagnosis
-
Depressive Disorder, Major / drug therapy
-
Depressive Disorder, Major / psychology
-
Diagnosis, Differential
-
Dose-Response Relationship, Drug
-
Drug Interactions
-
Drug Therapy, Combination
-
Female
-
Humans
-
Memantine / adverse effects
-
Memantine / therapeutic use
-
Nootropic Agents / adverse effects
-
Nootropic Agents / therapeutic use
-
Piperazines / adverse effects
-
Piperazines / therapeutic use*
-
Psychotherapy
-
Psychotic Disorders / diagnosis
-
Psychotic Disorders / drug therapy*
-
Psychotic Disorders / psychology
-
Quinolones / adverse effects
-
Quinolones / therapeutic use*
-
Risk Factors
-
Treatment Outcome
-
Venlafaxine Hydrochloride
Substances
-
Antidepressive Agents, Second-Generation
-
Antipsychotic Agents
-
Cyclohexanols
-
Nootropic Agents
-
Piperazines
-
Quinolones
-
Venlafaxine Hydrochloride
-
Aripiprazole
-
Memantine